METROPOLITAN LIFE INSURANCE CO/NY - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
METROPOLITAN LIFE INSURANCE CO/NY ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$8,408
-16.3%
7,1250.0%0.00%
Q2 2023$10,046
-76.7%
7,125
-59.5%
0.00%
-100.0%
Q4 2021$43,051
-10.5%
17,572
-7.9%
0.00%0.0%
Q3 2021$48,077
-56.4%
19,078
-50.7%
0.00%
-50.0%
Q2 2021$110,32138,7090.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders